Baudax Bio (BXRX) Prices Public Offering of Common Stock and Warrants
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/1/2026
- Wall St kicks off September under pressure as higher yields, oil prices weigh
- Oil prices rise 2% as US-Iran fighting stokes supply fears
- Two Saudi tankers struck in Strait of Hormuz Monday
- Fed’s Barr backs rate hike if inflation fails to cool, September odds hit 66%
- The Warsh pivot markets didn't expect
Baudax Bio Announces Pricing of Public Offering of Common Stock and Warrants
March 24, 2020 9:15 AM EDTMALVERN, Pa., March 24, 2020 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (Baudax or the Company) (Nasdaq: BXRX), a pharmaceutical company focused on therapeutics for acute care settings, today announced the pricing of an underwritten public offering of 7,692,308 shares of its common stock, Series A warrants to purchase 7,692,308 shares of common stock and Series B warrants to purchase 7,692,308 shares of common stock, at an exercise price of $4.59 per share for Series A Warrants and at an exercise price of $3.25 per share for Series B Warrants. Each share of common stock is being sold together... More
